Tenofovir disoproxil fumarate - Gilead Sciences
Alternative Names: Bis-POC-PMPA; GSK548470; PMPA-prodrug; Tenofovir DF; Tenozet; VireadLatest Information Update: 12 Jan 2022
Price :
$50 *
At a glance
- Originator Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
- Developer Gilead Sciences; GSK; University of California
- Class Antiretrovirals; Antivirals; Phosphonic acids; Purines; Small molecules
- Mechanism of Action Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B; HIV infections
Most Recent Events
- 06 Jul 2021 Arbutus Biopharma and Antios Therapeutics plans to initiate a Phase IIa ANTT201 clinical trial cohort in the second half of 2021
- 23 Jun 2021 Long-term efficacy and safety data from a phase III trial in Hepatitis B presented at the The International Liver Congress 2021 (ILC-2021)
- 01 Apr 2021 Launched for Hepatitis B (In children) in European Union, Norway, Iceland, Liechtenstein (PO)